Nucleus Genomics charges $9,999 to analyze up to 20 embryos: diseases, eye color, baldness, intelligence. According to the Financial Times, the service is available in more than 165 clinics. The investor is the Peter Thiel Founders Fund. The promise of the "best child" has become a paid genetic rating. The choice allows you to choose from existing embryos. Editing will change their DNA. Grain is funding editing research at Columbia University and intends to offer it to clients. Entrepreneur Kian Sadagi, founder of Keren, prepares buyers for the future service even before its scientific approval. Monet is raising about $30 million in 2025, with OpenAI CEO Sam Altman and Coinbase CEO Brian Armstrong among its investors. The company's founder, the biotechnologist Lucas Harrington, promises to first test the safety of correcting serious hereditary diseases. Bootstrap Bio shut down without new investment broke up after a conflict between the co-founders. Entrepreneur Katie Tay, who helped found Manhattan, launched Origin Genomics in March 2026. The previous companies did not make a scientific breakthrough. Customers are still interesting to investors. University science still brings uncomfortable news. In September 2026, Columbia University researcher Dieter Eagly and his colleagues reported in Nature that they had successfully mutated the PCSK9 gene in human embryos. Along the way, damage to chromosomes and mosaics occurred: embryonic cells received different DNA edits. When editor was introduced in the form of RNA, development was often arrested. The authors did not include reproductive applications of the current technology. Co-author Natan Teraf is the Medical Director of Grain. The article does not list her as one of the funders of the study. Changing a DNA signal does not exactly guarantee health. One gene can affect several functions of the body, and a hereditary error can be passed on to offspring.

Nucleus Genomics charges $9,999 to analyze up to 20 embryos: diseases, eye color, baldness, intelligence. According to the Financial Times, the service is available in more than 165 clinics. The investor is the Peter Thiel Founders Fund. The promise of the "best child" has become a paid genetic rating. The choice allows you to choose from existing embryos. Editing will change their DNA. Grain is funding editing research at Columbia University and intends to offer it to clients. Entrepreneur Kian Sadagi, founder of Keren, prepares buyers for the future service even before its scientific approval. Monet is raising about $30 million in 2025, with OpenAI CEO Sam Altman and Coinbase CEO Brian Armstrong among its investors. The company's founder, the biotechnologist Lucas Harrington, promises to first test the safety of correcting serious hereditary diseases. Bootstrap Bio shut down without new investment broke up after a conflict between the co-founders. Entrepreneur Katie Tay, who helped found Manhattan, launched Origin Genomics in March 2026. The previous companies did not make a scientific breakthrough. Customers are still interesting to investors. University science still brings uncomfortable news. In September 2026, Columbia University researcher Dieter Eagly and his colleagues reported in Nature that they had successfully mutated the PCSK9 gene in human embryos. Along the way, damage to chromosomes and mosaics occurred: embryonic cells received different DNA edits. When editor was introduced in the form of RNA, development was often arrested. The authors did not include reproductive applications of the current technology. Co-author Natan Teraf is the Medical Director of Grain. The article does not list her as one of the funders of the study. Changing a DNA signal does not exactly guarantee health. One gene can affect several functions of the body, and a hereditary error can be passed on to offspring.